查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1995405

药用明胶市场：按类型、形态、原料、应用和分销管道划分－2026-2032年全球市场预测

Pharmaceutical Gelatin Market by Type, Form, Raw Material, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，药用明胶市场价值将达到 13 亿美元，到 2026 年将成长到 13.8 亿美元，到 2032 年将达到 19.8 亿美元，复合年增长率为 6.18%。

主要市场统计数据
基准年 2025 13亿美元
预计年份：2026年 13.8亿美元
预测年份 2032 19.8亿美元
复合年增长率 (%) 6.18%

全面概述影响配方和采购决策的药用明胶的基本原理、监管要求和供应考虑因素。

医薬用ゼラチンは、製剤、カプセル化、コーティング用途において极めて重要な役割を果たしており、素材の品质は製品の安定性や患者の治疗成果に直接影响を与えます。本执行摘要の导入では、ゼラチンの机能的特性（生体适合性、皮膜形成能力、および制御された溶解挙动）を说明するとともに、剤形开発のライフサイクル全体におけるゼラチンの位置づけを明らかにします。规制当局の监视、サプライチェーンの継続性、および原材料のトレーサビリティは、调达および製剤のリスクプロファイルを决定づける中心的なテーマです。

永续性、先进分析和不断提高的品质期望如何改变明胶的采购、製造实践和供应商伙伴关係。

医薬品用ゼラチンの业界では、筹资策略や製品开発の道筋を再构筑する収束的な変化が起きています。サステナビリティや动物福祉への関心の高まりにより、原材料の产地や製作流程に対する监视が强化され、メーカーはトレーサビリティ体制の拡充や代替供给源の模索を迫られています。一方、分析化学やプロセスバリデーションの进歩により、品管の基准が引き上げられ、ロット间の残留溶媒、微生物限度、机能性能について、より详细な试験が求められるようになっています。

评估累积关税对影响明胶采购、库存策略、配方开发时间表和供应商多元化的韧性措施的影响。

近年の関税赋课や贸易政策の転换は、世界のサプライチェーンで事业を展开するゼラチン购入者や製造业者にとって、调达计画やコスト构造に新たな动きをもたらしました。多重の関税は、着荷コストだけでなく、サプライヤーの选定、在库戦略、そして原材料调达先の地理的分散にも影响を及ぼします。これに対応し、调达チームは関税変动によるリスクを軽减するため、垂直统合の选択肢や在地采购を再评価しています。

综合細項分析揭示了采购来源、类型、形式、用途和通路的选择如何全面决定明胶的性能和供应风险状况。

素材の选定、加工方法、流通チャネルの动向に焦点を当てた复数の分析的观点を通じて市场を检验することで、市场セグメンテーションに関する洞察が得られます。牛、鱼、豚の各原产地による原料の差异を検讨する际、それぞれの选択肢には、製品设计の决定や市场での受容性を左右する、特有の官能的、文化的、规制上の考虑事项が存在します。原料の选定は、多くの场合、最终市场の感性、地域の食习惯上の制约、および剤形に求められる特定の机能的特性によって左右されます。

将区域趋势进行比较，解释美洲、欧洲、中东和非洲以及亚太地区的差异如何影响采购、合规和打入市场策略。

地域ごとの动向は、调达オプション、法律规范、および最终市场の需要パターンに顕着な影响を及ぼします。アメリカ大陆では、购买戦略は、确立された製造群、トレーサビリティに対する规制上の期待、およびカプセルやコーティング用の幅広いゼラチングレードを支える成熟した供给基盘によって形作られることがよくあります。この地域の生产および流通ネットワークは、タイムリーな物流と规制顺守を优先しており、これがサプライヤーの合格性评価通讯协定や在库配置の指南となっています。

透过可追溯性、分析能力、共享品质协议和增值技术服务来强调供应商差异化的竞争优势。

ゼラチン分野における竞争考察は、価格のみではなく、トレーサビリティ、品质保证、および技术サービスにおけるサプライヤーの能力に焦点を当てています。主要サプライヤーは、上游工程のトレーサビリティシステム、高度な分析研究所、およびカプセルメーカーやコーティング製剤メーカー向けのカスタマイズされた製品开発支援への投资を通じて差别化を図っています。これらの能力により、サプライヤーは、顾客固有の规制関连资料に対応しつつ、厳格な溶解性および安定性要件を満たす仕様を共同で策定することが可能になります。

供应商和製造商可采取的策略重点，以增强可追溯性、实现采购多元化、提高分析保证和扩大增值技术服务。

业界の领导企业は、供给の确実性、製品の性能、および规制への适合性を高める戦略的取り组みを优先すべきです。原材料の产地から完成品に至るまでの包括的なトレーサビリティシステムへの投资は、コンプライアンスリスクを低减し、商业性的関係を强化することになります。同様に重要なのは、机能性能试験をサポートする高度な分析プラットフォームの导入であり、これにより製造バッチ间でのカプセルおよびコーティングの挙动の一贯性を高めることが可能になります。

采用透明的混合方法研究设计，结合相关人员访谈、技术文献整合、贸易流量分析和专家检验，确保获得可靠的策略见解。

本执行摘要の基础となる调查方法は、一次调査と二次检验を融合させ、坚牢かつ実用的な知见を确保するものです。一次调査の主な入力情报には、製造およびサプライヤー组织全体の调达责任者、製剤开発者、品质保证负责人に対する构造化インタビューが含まれます。これらの対话を通じて、调达决定の基准、品质への期待、および贸易措置や规制変更への业务上の适応に関する背景情报が得られます。

综合结论强调，需要将明胶的选择视为一项跨部门的策略决策，该决策应基于产地、分析数据和供应弹性。

この结论は、本执行摘要の中心的なテーマを统合したものです。すなわち、ゼラチンの素材特性と产地は、製剤の成功、规制顺守、市场での受容性を决定づける要因として、ますます重要性を増しています。利害相关人员は、サステナビリティへの期待、厳格化された分析基准、贸易関连のコスト変动といった、相互に作用するプレッシャーに対处しなければなりません。これらは総合的に、调达およびイノベーションの选択肢を形作っています。したがって、レジリエンスは、调达先の多様化、坚牢なトレーサビリティ、そしてサプライヤーと製造业者间の付加価値のある技术的连携を通じて构筑されるのです。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 药用明胶市场：按类型划分

  • A型
  • B型

第九章：药用明胶市场：依形态划分

  • 粉末
  • 座位

第十章：药用明胶市场：依原料划分

  • 皮革
  • 骨
  • 皮与骨的混合物

第十一章 药用明胶市场：依应用领域划分

  • 硬胶囊
  • 颗粒
  • 软胶囊
  • 药片包衣

第十二章 药用明胶市场：依分销管道划分

  • 离线
  • 在线的

第十三章 药用明胶市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 药用明胶市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 药用明胶市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国药用明胶市场

第十七章：中国药用明胶市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Danish Crown Protein A/S
  • Darling Ingredients Inc.
  • Gelco International
  • Gelita AG
  • Italgelatin SpA
  • Lonza Group AG
  • MV Protein Inc.
  • Nippi Inc.
  • Nitta Gelatin Inc.
  • Norland Products Inc.
  • PB Leiner NV
  • Tessenderlo Group NV
  • Weishardt International SAS
Product Code: MRR-4F4C36263656

The Pharmaceutical Gelatin Market was valued at USD 1.30 billion in 2025 and is projected to grow to USD 1.38 billion in 2026, with a CAGR of 6.18%, reaching USD 1.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.30 billion
Estimated Year [2026] USD 1.38 billion
Forecast Year [2032] USD 1.98 billion
CAGR (%) 6.18%

Comprehensive contextual orientation to pharmaceutical gelatin fundamentals, regulatory expectations, and supply considerations that drive formulation and sourcing decisions

Pharmaceutical gelatin occupies a pivotal role across formulation, encapsulation, and coating applications, where material integrity directly influences product stability and patient outcomes. The introduction to this executive summary establishes the material's functional attributes-biocompatibility, film-forming capability, and controlled dissolution behavior-while situating gelatin within the broader lifecycle of dosage-form development. Regulatory scrutiny, supply chain continuity, and raw material traceability are central themes that determine procurement and formulation risk profiles.

As the industry shifts toward patient-centric dosage forms and sustainable sourcing, gelatin suppliers and pharmaceutical manufacturers must reconcile performance demands with ethical and regulatory expectations. Emerging quality frameworks emphasize documentation from source to finished product, requiring closer collaboration between capsule makers, active pharmaceutical ingredient formulators, and analytical labs. Consequently, strategic decisions about source selection, processing parameters, and supplier qualification now factor prominently into commercial development plans.

Taken together, the introduction frames gelatin not merely as an inert excipient but as a material whose provenance, form, and processing influence regulatory outcomes, manufacturing efficiency, and therapeutic performance. The subsequent sections delve into transformative shifts, tariff impacts, segmentation insights, regional dynamics, competitive positioning, actionable recommendations, methodology, and concluding reflections that support commercially defensible decision-making.

How sustainability, advanced analytics, and heightened quality expectations are collectively reshaping gelatin sourcing, manufacturing practices, and supplier partnerships

The landscape for pharmaceutical gelatin is experiencing convergent changes that are reshaping sourcing strategies and product development pathways. Rising emphasis on sustainability and animal welfare has intensified scrutiny on raw material origin and processing, prompting manufacturers to expand traceability mechanisms and seek alternative sources. Meanwhile, advances in analytical chemistry and process validation have raised the bar for quality control, requiring more granular testing for residual solvents, microbial limits, and functional performance across lots.

Concurrently, digital supply chain technologies and near-real-time analytics are enabling tighter inventory control and better visibility into upstream raw material flows. These capabilities reduce batch-to-batch variability and support just-in-time manufacturing without sacrificing compliance. Additionally, customer preferences toward clean-label and ethically sourced ingredients influence procurement policies, driving premium positioning for suppliers who can certify responsible sourcing.

Taken together, these shifts are transforming commercial relationships: purchasers increasingly demand long-term partnerships founded on shared quality systems and transparency. As a result, companies that proactively invest in traceability, environmental stewardship, and robust testing protocols are better positioned to capture formulators seeking reliable gelatin supplies for modern pharmaceutical applications.

Assessment of cumulative tariff effects on gelatin procurement, inventory strategies, and resilience measures that influence formulation timelines and supplier diversification

The imposition of tariffs and trade policy shifts in recent years has introduced new dynamics to procurement planning and cost structures for gelatin buyers and manufacturers operating in global supply chains. Tariff layers affect not only landed cost but also supplier selection, inventory strategy, and the geographic diversification of raw material sources. In response, procurement teams have re-evaluated vertical integration options and local sourcing to mitigate exposure to customs volatility.

Tariff-driven cost pressures have encouraged companies to pursue more rigorous supplier audits and to negotiate longer-term contracts that lock in supply terms and stability. At the same time, organizations have adopted hedging strategies across multiple sourcing regions to preserve continuity of supply when trade measures disrupt conventional shipping lanes. These adjustments are complemented by operational adaptations such as increased safety stock at strategically located manufacturing sites and closer alignment between commercial planning and logistics teams.

Importantly, the cumulative impact of tariffs extends beyond per-unit cost; it influences innovation timelines and market entry strategies. Firms evaluating new capsule formats or coating technologies now incorporate tariff scenarios into feasibility assessments and go-to-market projections. Overall, trade measures have catalyzed more resilient supply chain design, emphasizing flexibility, multi-sourcing, and contractual mechanisms that balance cost management with uninterrupted access to quality gelatin.

Integrated segmentation analysis revealing how source, type, form, application, and distribution choices collectively determine gelatin performance and supply risk profiles

Segmentation insight emerges when the market is examined through multiple analytical lenses that highlight material selection, processing choices, and channel dynamics. When considering source differentiation across bovine, fish, and porcine origins, each option presents distinctive sensory, cultural, and regulatory considerations that shape formulation decisions and market acceptability. Source selection is often driven by end-market sensitivities, regional dietary constraints, and the specific functional attributes required by the dosage form.

Evaluating the material by type-Type A versus Type B-reveals differences in gel strength and isoelectric properties that influence hydration, gelling behavior, and interaction with active ingredients. These type-driven characteristics guide technologists when optimizing capsule hardness, dissolution profiles, and compatibility with encapsulated actives. Form factor distinctions between powder and sheet formats affect manufacturing throughput, handling, and dissolution kinetics; powder forms lend themselves to flexible dosing and rapid blending, whereas sheets support continuous encapsulation lines and can influence film uniformity.

Application-based segmentation-encompassing hard capsule, pellets, soft capsule, and tablet coating-demonstrates how functional requirements vary across dosage forms, requiring tailored gelatin grades, plasticizer systems, and processing conditions. Distribution channels-direct procurement, distributor-mediated supply, and online sourcing-create different risk exposures and service expectations, with direct relationships favoring customized technical support and online channels offering procurement speed and price transparency. By integrating these segmentation dimensions, stakeholders can align product specifications and supply strategies with formulation goals and market access requirements.

Comparative regional dynamics explaining how Americas, Europe, Middle East & Africa, and Asia-Pacific variations drive sourcing, compliance, and market access strategies

Regional dynamics exert a pronounced influence on sourcing options, regulatory frameworks, and end-market demand patterns. In the Americas, purchasing strategies are often shaped by established manufacturing clusters, regulatory expectations for traceability, and a mature supply base that supports a range of gelatin grades for capsules and coatings. Production and distribution networks in this region prioritize timely logistics and regulatory compliance, which informs supplier qualification protocols and inventory positioning.

Europe, Middle East & Africa present a complex mosaic of regulatory regimes, cultural dietary requirements, and demand heterogeneity. Manufacturers in this region weigh halal, kosher, and other certification needs alongside environmental considerations, which affects source selection and supplier auditing practices. The region's regulatory scrutiny emphasizes documentation and adherence to sanitary standards, thereby elevating the importance of supplier transparency and provenance controls.

Asia-Pacific remains a dynamic region with expanding pharmaceutical manufacturing capacity, diverse raw material endowments, and evolving quality norms. Rapid growth in contract manufacturing and generic production has increased demand for reliable gelatin supplies, while local sourcing strategies seek to balance cost competitiveness with international compliance expectations. Across regions, cross-border logistics, certification requirements, and cultural preferences continue to shape where and how gelatin is sourced and deployed.

Competitive profile emphasizing supplier differentiation through traceability, analytical capabilities, collaborative quality agreements, and value-added technical services

Competitive insight in the gelatin arena centers on supplier capabilities in traceability, quality assurance, and technical service rather than solely on price. Leading suppliers differentiate through investments in upstream traceability systems, advanced analytical laboratories, and customized product development support for capsule manufacturers and coating formulators. These capabilities enable suppliers to co-develop specifications that meet stringent dissolution and stability requirements while addressing client-specific regulatory dossiers.

Partnership models have evolved to include collaborative quality agreements, joint risk assessments, and multi-year supply commitments that provide security for both downstream manufacturers and upstream producers. Companies that maintain diversified raw material procurement strategies and multi-modal logistics options are more resilient in the face of disruption. Additionally, organizations that provide transparent documentation, such as chain-of-custody certificates and third-party audit reports, gain preferential consideration among quality-driven buyers.

From a commercialization perspective, suppliers that offer formulation advisory services, rapid-response stability testing, and tailored packaging options command higher strategic value. These services reduce time-to-market for new dosage forms and support rapid scale-up, thereby strengthening customer retention and enabling premium positioning in a market where regulatory compliance and product performance are paramount.

Actionable strategic priorities for suppliers and manufacturers to strengthen traceability, diversify sourcing, enhance analytical assurance, and expand value-added technical services

Industry leaders should prioritize strategic initiatives that enhance supply assurance, product performance, and regulatory alignment. Investing in comprehensive traceability systems from raw material origin through finished product will reduce compliance risk and strengthen commercial relationships. Equally important is the adoption of advanced analytical platforms that support functional performance testing, enabling more consistent capsule and coating behavior across production batches.

Operationally, establishing multi-sourcing strategies and geographically diversified inventories can reduce exposure to trade policy shifts and logistics disruptions. Leaders should formalize supplier partnerships through performance-based contracts and mutual contingency planning, which fosters supply stability and shared accountability. On the commercial front, positioning gelatin offerings with documented sustainability attributes and certification credentials addresses buyer preferences and opens access to markets with dietary or ethical constraints.

Finally, companies should expand value propositions by bundling technical support, stability testing, and rapid-response troubleshooting to accelerate customer product development cycles. By aligning technical services with strategic sourcing and robust quality systems, industry leaders will strengthen market positioning and enable customers to deliver safer, more reliable dosage forms to patients.

Transparent mixed-method research design combining stakeholder interviews, technical literature synthesis, trade flow analysis, and expert validation to ensure reliable strategic insights

The research methodology underpinning this executive summary blends primary engagement and secondary validation to ensure robust, actionable insights. Primary inputs include structured interviews with procurement leaders, formulation scientists, and quality assurance professionals across manufacturing and supplier organizations. These dialogues provide context on sourcing decision criteria, quality expectations, and operational adaptations to trade measures and regulatory changes.

Secondary analysis synthesizes peer-reviewed literature, regulatory guidance documents, and publicly available technical specifications to validate functional assumptions about gelatin types, forms, and application-specific requirements. Trade flow and logistics data inform considerations about cross-border sourcing and inventory strategies, while case studies illustrate practical responses to supply disruptions and certification demands. Triangulation across these sources ensures that conclusions reflect both practitioner experience and documented standards.

Throughout the methodology, emphasis is placed on transparency of assumptions, reproducibility of analytical approaches, and the use of multiple corroborating data points to support each thematic insight. Quality controls include cross-validation of interview findings, review of technical specifications by subject-matter experts, and iterative refinement of conclusions to reflect stakeholder feedback.

Consolidated conclusion highlighting the need to treat gelatin selection as a cross-functional strategic decision driven by provenance, analytics, and supply resilience

The conclusion synthesizes the executive summary's central themes: gelatin's material attributes and provenance are increasingly determinative of formulation success, regulatory compliance, and market acceptance. Stakeholders must navigate converging pressures from sustainability expectations, heightened analytical standards, and trade-related cost fluctuations, which collectively shape procurement and innovation choices. Resilience is therefore built through diversified sourcing, robust traceability, and value-added technical collaboration between suppliers and manufacturers.

Forward-looking organizations will treat gelatin selection as a cross-functional decision involving procurement, R&D, quality, and regulatory affairs rather than a commoditized purchasing choice. By integrating technical support, sustainability credentials, and formalized supplier risk management into procurement frameworks, manufacturers can better assure product performance and regulatory readiness. In sum, the path to competitive advantage lies in aligning material science rigor with supply chain resilience and customer-centric service offerings that accelerate development timelines and support compliant commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmaceutical Gelatin Market, by Type

  • 8.1. Type A
  • 8.2. Type B

9. Pharmaceutical Gelatin Market, by Form

  • 9.1. Powder
  • 9.2. Sheet

10. Pharmaceutical Gelatin Market, by Raw Material

  • 10.1. Skin
  • 10.2. Bone
  • 10.3. Combined Skin And Bone

11. Pharmaceutical Gelatin Market, by Application

  • 11.1. Hard Capsule
  • 11.2. Pellets
  • 11.3. Soft Capsule
  • 11.4. Tablet Coating

12. Pharmaceutical Gelatin Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Pharmaceutical Gelatin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pharmaceutical Gelatin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pharmaceutical Gelatin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pharmaceutical Gelatin Market

17. China Pharmaceutical Gelatin Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Danish Crown Protein A/S
  • 18.6. Darling Ingredients Inc.
  • 18.7. Gelco International
  • 18.8. Gelita AG
  • 18.9. Italgelatin SpA
  • 18.10. Lonza Group AG
  • 18.11. MV Protein Inc.
  • 18.12. Nippi Inc.
  • 18.13. Nitta Gelatin Inc.
  • 18.14. Norland Products Inc.
  • 18.15. PB Leiner NV
  • 18.16. Tessenderlo Group NV
  • 18.17. Weishardt International SAS

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACEUTICAL GELATIN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PHARMACEUTICAL GELATIN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE A, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE A, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE A, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SHEET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SHEET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SHEET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SKIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SKIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SKIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY BONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY BONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY BONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY COMBINED SKIN AND BONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY COMBINED SKIN AND BONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY COMBINED SKIN AND BONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY HARD CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY HARD CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY HARD CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY PELLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY PELLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY PELLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SOFT CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SOFT CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY SOFT CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TABLET COATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TABLET COATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY TABLET COATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 106. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GCC PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 123. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. G7 PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 129. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 130. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PHARMACEUTICAL GELATIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, BY RAW MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA PHARMACEUTICAL GELATIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)